...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: For sake of argument lets say ..
1
May 31, 2022 11:06AM

Fuzzy, i doubt you would see any significant movement of ZHCLF on the  expert market prior to a BP deal.  i think it is a bit early for a BP deal but deals are getting done in a phase 1 and phase 2 trials so you never know.  DM needs to pull a rabbit out of a hat and something big done at Zenith soon to give some sort of credibility to this management team. 

 

 

Share
New Message
Please login to post a reply